tp53 (do-7; ready to use, cat. no. ir 616) (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
tp53 (do-7; ready to use, cat. no. ir 616)
Tp53 (Do 7; Ready To Use, Cat. No. Ir 616), supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ready+to+use+do+7/pm38137536-58-67-84
Average 90 stars, based on 1 article reviews
Tp53 (Do 7; Ready To Use, Cat. No. Ir 616), supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ready+to+use+do+7/pm38137536-58-67-84
Average 90 stars, based on 1 article reviews
tp53 (do-7; ready to use, cat. no. ir 616) - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
In Situ Hybridization:Article Title: Cribriform morular thyroid carcinoma: a case report with pathological, immunohistochemical, and molecular findings suggesting an origin from follicular cells (or their endodermal precursors) Article Snippet: The primary antibodies (clone, concentration, antigenic recovery treatment, and manufacturer) in the cell block sections were as follows: thyroglobulin (2H11 + 6E1, ready to use; Roche Diagnostics, San Cugat del Vallés, Spain), TTF1 (SPT24, pH 6; Leica Biosystems, Newcastle Upon Tyne, UK), PAX8 (MRQ-50, ready to use; Roche Diagnostics), and calcitonin (polyclonal, A0576, 1:400; Dako). .. For the tissue sections, the antibodies used were the following: thyroglobulin (polyclonal, ready to use, pH 6; Dako), thyroperoxidase (MoAb47, 1/50, pH 9; Dako), TTF1 (SPT24, 1/100, pH 9; Gennova, Sevilla, Spain), PAX8 (SP348, 1/100, pH 9; Gennova), cytokerantin 7 (CK7) (OV-TL 12/30, ready to use, pH 9; Dako), CK20 (Ks 20.8, ready to use, pH 9; Dako), CK5/6 (D5/16B4, ready to use, pH 9; Dako), sodium-iodide symporter (NIS) (FP5A, prediluted, pH 9; NeoMarkers, Fremont, CA, USA), galectin-3 (GAL3-3B8, 1:100, pH 9; Biocare Medical, Madrid, Spain),estrogen receptor-α (EP1/IR044IVD, ready to use, pH 9; Dako), progesterone receptor (PgR 636/IR068, ready to use, pH 9; Dako), β-catenin (β-catenin-1, ready to use, pH 9; Dako), other:Article Title: Diagnostic value of MDM2 RNA in situ hybridization for low-grade osteosarcoma: Consistency comparison of RNA in situ hybridization, fluorescence in situ hybridization, and immunohistochemistry. Article Snippet: Detection of MDM2 gene amplification via fluorescence in situ hybridization (FISH) and MDM2 overexpression by immunohistochemistry (IHC) have been utilized for the diagnosis of low-grade osteosarcoma (LGOS).. The aim of this study was to evaluate the diagnostic value of MDM2 RNA in situ hybridization (RNA-ISH) and compare this assay with MDM2 FISH and IHC in distinguishing LGOS from its histologic mimics.. MDM2 RNA-ISH, FISH and IHC were performed on nondecalcified samples of 23 LGOSs and 52 control cases. Article Title: Prognostic Value of ATRX and p53 Status in High-Grade Glioma Patients in Morocco Article Snippet: Immunohistochemistry (IHC) An immunohistochemical study was carried out using three antibodies: IDHR132H (clone H09, 1:20 dilution, ph9) from Dianova (BIOZOL, Berlin, Germany), p53 (clone DO-7, ready to use, pH9) from Article Title: p53 AS A POTENTIAL ACTIONABLE TARGET IN MYXOFIBROSARCOMA: MOLECULAR AND PATHOLOGICAL REVIEW OF A SINGLE-INSTITUTE SERIES. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: Pathologic Characteristics of Somatotroph Pituitary Tumors-An Observational Single-Center Study. Article Snippet: The antibodies used for the majority of cases are as follows: antibodies against growth hormone (GH, cat. no. MS-1328-P1), prolactin (PRL, cat. no. MS-1362-P1), ACTH (cat. no. MS-452-P1) and β-TSH (cat. no. MS-1453-P1) from EPREDIA/Thermo Fisher Scientific Inc., Waltham, MA, USA; β-FSH (clone C10; cat. no. M3504), and Article Title: Single Center Characterization of a Cohort of Salivary Gland Carcinomas Article Snippet: The following antibodies were used: Anti-human p53 protein (DO-7, ready-to-use dilution, Immunohistochemistry:Article Title: High Effectiveness of Lenvatinib Plus Pembrolizumab in the NSMP/MMRd Molecular Subtype of Endometrial Cancer: A Real-World Data Analysis Article Snippet: .. Immunohistochemistry We used Bioprocessing:Article Title: High Effectiveness of Lenvatinib Plus Pembrolizumab in the NSMP/MMRd Molecular Subtype of Endometrial Cancer: A Real-World Data Analysis Article Snippet: .. Immunohistochemistry We used Mutagenesis:Article Title: <i>TERT</i> Promoter Mutation c.-124C&gt;T Commonly Occurs in Low-Grade Fibromatosis-like Metaplastic Breast Carcinoma Article Snippet: All cases were completely immunonegative for ER (ready to use; clone SP1, Roche), PR (ready to use; clone 1E2, Roche), and HER2 (ready to use; clone 4B5, Roche). .. Furthermore, all cases were immunonegative for b-catenin (ready to use; Cell 1452 Arch Pathol Lab Med—Vol 147, December 2023 TERT Promoter Mutation c.-124C.T in FLMC—Webersinke et al Marque), and none of the cases revealed |